Aortic Valve Disease

The Boston Scientific Next Generation Acurate Neo2™ Aortic Valve System Demonstrates Favorable Outcomes In Clinical Practice - September 10, 2018

A new study evaluating the safety and performance of the Boston Scientific ACURATE neo2™ Aortic Valve System, a next generation transcatheter aortic valve implantation (TAVI) system, demonstrated a high procedural...

Read more

Boston Scientific Prevails in U.K. Edwards Lifesciences Litigation- March 28, 2018

Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal  dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device infringes Boston Scientific patent EP (UK) 2 926 766 and that all claims of that patent are valid... 

Read more

The Boston Scientific LOTUS™ Valve System demonstrated superior efficacy to CoreValve® in global REPRISE III trial at one year - May 16, 2017

Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris.  Data from the study demonstrated that... 

Read more

Boston Scientific Closes Symetis Acquisition - May 16, 2017
Acquisition Expands Company’s Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease.

Read more

Boston Scientific Receives CE Mark For LOTUS Edge™ Valve System - Sep 19, 2016

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology.

Read more

SEE ALL PRESS RELEASES

20162015 

Top